Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab sequential neoadjuvant therapy for locally advanced ESCC
NCT05189730Phase 2Active, not recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Jul 2021
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sichuan Cancer Hospital. Primary endpoints: Complete Pathologic Response Rate at 3 months and Incidence of Adverse Events at 6 months. Started Jul 2021; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05189730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05189730.